A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT ID: NCT06748053
Last Updated: 2025-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
300 participants
INTERVENTIONAL
2025-02-10
2027-01-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.
NCT00603382
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
NCT01000506
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
NCT03207243
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma
NCT01823016
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A: Dose Finding - GSK5784283
GSK5784283
GSK5784283 will be administered.
Part A: Dose Finding - Placebo
Placebo
Placebo will be administered.
Part B: Extended Dosing - GSK5784283
GSK5784283
GSK5784283 will be administered.
Part B: Extended Dosing - Placebo
Placebo
Placebo will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GSK5784283
GSK5784283 will be administered.
Placebo
Placebo will be administered.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed Consent: Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol. The participant must be willing and able to comply with trial and follow-up procedures.
* Age: Participants must be 18 to 75 years of age inclusive, at the time of signing the informed consent.
* Documented physician-diagnosed asthma for \>= 2 years that meets the National Heart, Lung, and Blood Institute guidelines
* Evidence of variable airflow obstruction consistent with asthma.
* Documented history of asthma exacerbation within 12 months prior to Visit 1.
* An asthma exacerbation defined as a worsening of asthma symptoms.
* A well- documented requirement for regular treatment with medium or high-dose ICS for at least 6 months prior to screening.
* At least one additional maintenance asthma controller medication is required according to standard practice of care (e.g., long-acting beta 2 agonist (LABA), leukotriene receptors antagonists (LTRA), theophylline, long-acting muscarinic antagonist (LAMA), chromones, etc.). Use of additional asthma controller medications must be documented for at least 3 months prior to Visit 1.
* Weight \>=40 kg.
* Male or eligible Female.
* Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
* Not a woman of childbearing potential (WONCBP) OR
* Is a WOCBP and using a contraceptive method that is highly effective, with a failure rate of \<1%, 28 days prior to the 1st dose of the study drug and during the study intervention period and follow-up period. The investigator should evaluate potential for contraceptive method failure (e.g. non-compliance, recently initiated) in relationship to the first dose of study intervention.
* A WOCBP must have a negative serum pregnancy test at screening and a highly sensitive pregnancy test (\[urine or serum\] as required by local regulations) within 24 hours before each dose of study intervention.
* If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
* The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
* Contraceptive use by women should be consistent with location regulations regarding the methods of highly effective contraception for those participating in clinical trials.
Exclusion Criteria
• Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (e.g., current upper or lower respiratory tract infection, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome, primary ciliary dyskinesia).
Helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
* Active or latent tuberculosis:
* Participants with a diagnosis or evidence of active or latent tuberculosis are excluded from the study.
* Diagnosis of vocal cord dysfunction, dysfunctional breathing, or pseudo steroid resistant asthma.
* Malignancy: A current malignancy or previous history of cancer in remission for less than 5 years prior to screening (Participants that had localized carcinoma of the skin which was resected for cure will not be excluded).
* History of an unresolved clinically significant infection within 30 days prior to Visit 1.
* A known immunodeficiency (e.g. human immunodeficiency virus - HIV), other than that explained by the use of corticosteroids taken as therapy for asthma.
* Participants who have known, pre-existing, clinically significant cardiac, endocrine, autoimmune, rheumatologic, metabolic, neurological, renal, gastrointestinal, hepatic, hematological or any other system abnormalities that are uncontrolled with standard treatment including eosinophilic conditions such as hyper-eosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA).
* Any clinically relevant abnormal findings in physical examination, hematology, clinical chemistry, urinalysis, vital signs at Visit 2 which in the opinion of the investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to participate in the study.
* Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives prior to Visit 1, whichever is longer and up until the end of study.
* Receipt of any investigational non-biologic agent within 30 days or 5 half-lives prior to screening, whichever is longer and up until the end of study.
* Experimental vaccines are not permitted within 30 days prior to randomization and up until the end of the study.
* Use of immunosuppressive medication (e.g., methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, systemic (oral) corticosteroids) within 3 months prior to Visit 1 and up until the end of study.
* Systemic corticosteroid burst including taper within 15 days prior to Visit 1 or during the screening/run-in period.
* Subjects who have not responded to Tezepelumab treatment.
* Receipt of live or live attenuated vaccine(s) within 30 days prior to randomization or plans to receive such vaccines up until the end of study.
* A positive human immunodeficiency virus (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
* Positive test for hepatitis B virus (HBV) defined as either:
1. positive for hepatitis B surface antigen (HBsAg) OR
2. positive for HBV DNA
* Positive Hepatitis C antibody test result.
* Positive Hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
* Current smokers (tobacco and marijuana) or former smokers with a smoking history \>=10 pack years and subjects using vaping products, including electronic cigarettes.
* History of chronic alcohol or drug abuse within 2 years.
* History of severe allergic reaction, anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) to any biologic therapy.
* History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor contraindicates their participation.
* Participants who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations.
* Participants who meet the following based on results from sample taken at Visit 2:
1. Alanine aminotransferase (ALT) \>2x upper limit of normal (ULN)
2. Total bilirubin \>1.5x ULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
3. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
* QTcF \>= 450 msec or QTcF \>= 480 msec for patients with bundle branch block or an abnormal ECG finding that is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the investigator in the 12-Lead ECG central over-read from screening Visit 2.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Redding, California, United States
GSK Investigational Site
San Jose, California, United States
GSK Investigational Site
Lakewood, Colorado, United States
GSK Investigational Site
Wheat Ridge, Colorado, United States
GSK Investigational Site
Aventura, Florida, United States
GSK Investigational Site
Hialeah, Florida, United States
GSK Investigational Site
Lake Worth, Florida, United States
GSK Investigational Site
Leesburg, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Plantation, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Shreveport, Louisiana, United States
GSK Investigational Site
Dearborn, Michigan, United States
GSK Investigational Site
Lathrup Village, Michigan, United States
GSK Investigational Site
The Bronx, New York, United States
GSK Investigational Site
Pineville, North Carolina, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
DuBois, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Wyomissing, Pennsylvania, United States
GSK Investigational Site
Warwick, Rhode Island, United States
GSK Investigational Site
Greenville, South Carolina, United States
GSK Investigational Site
Knoxville, Tennessee, United States
GSK Investigational Site
Boerne, Texas, United States
GSK Investigational Site
Cypress, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Seabrook, Texas, United States
GSK Investigational Site
American Fork, Utah, United States
GSK Investigational Site
Pleasant View, Utah, United States
GSK Investigational Site
South Ogden, Utah, United States
GSK Investigational Site
Blagoevgrad, , Bulgaria
GSK Investigational Site
Lovech, , Bulgaria
GSK Investigational Site
Pazardzhik, , Bulgaria
GSK Investigational Site
Plovdiv, , Bulgaria
GSK Investigational Site
Rousse, , Bulgaria
GSK Investigational Site
Rousse, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Stara Zagora, , Bulgaria
GSK Investigational Site
Varna, , Bulgaria
GSK Investigational Site
Vratsa, , Bulgaria
GSK Investigational Site
Kelowna, British Columbia, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Windsor, Ontario, Canada
GSK Investigational Site
Trois-Rivières, Quebec, Canada
GSK Investigational Site
Mladá Boleslav, , Czechia
GSK Investigational Site
Teplice, , Czechia
GSK Investigational Site
Bendorf, , Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Darmstadt, , Germany
GSK Investigational Site
Fürstenwalde, , Germany
GSK Investigational Site
Magdeburg, , Germany
GSK Investigational Site
München, , Germany
GSK Investigational Site
Chiba, , Japan
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Fukushima, , Japan
GSK Investigational Site
Gifu, , Japan
GSK Investigational Site
Hokkaido, , Japan
GSK Investigational Site
Hyōgo, , Japan
GSK Investigational Site
Mie, , Japan
GSK Investigational Site
Nagasaki, , Japan
GSK Investigational Site
Okayama, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Yokohama, , Japan
GSK Investigational Site
Alcorcon Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-518321-15
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
223125
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.